These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. Gomella LG BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166 [TBL] [Abstract][Full Text] [Related]
24. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Collier A; Ghosh S; McGlynn B; Hollins G Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430 [TBL] [Abstract][Full Text] [Related]
25. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S J Androl; 2006; 27(6):725-8. PubMed ID: 16775253 [TBL] [Abstract][Full Text] [Related]
26. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Yaturu S; DjeDjos S; Alferos G; Deprisco C Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350 [TBL] [Abstract][Full Text] [Related]
27. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. Wadhwa VK; Weston R; Mistry R; Parr NJ BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564 [TBL] [Abstract][Full Text] [Related]
28. Long term androgen deprivation therapy in prostate cancer. Ockrim JL; Abel PD BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586 [No Abstract] [Full Text] [Related]
29. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Greiman AK; Keane TE Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429 [TBL] [Abstract][Full Text] [Related]
30. Metabolic effects of androgen deprivation therapy. Choi SM; Kam SC Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932 [TBL] [Abstract][Full Text] [Related]
31. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067 [TBL] [Abstract][Full Text] [Related]
32. Managing complications of androgen deprivation therapy for prostate cancer. Holzbeierlein JM Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456 [TBL] [Abstract][Full Text] [Related]
33. Metabolic complications of androgen deprivation therapy for prostate cancer. Saylor PJ; Smith MR J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628 [TBL] [Abstract][Full Text] [Related]
34. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
39. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Smith MR Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892 [TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]